)
Drug majors Sun Pharmaceutical and AstraZeneca Pharma India (AZPIL) today said they have entered into a distribution services agreement to distribute AstraZeneca's heart disease treatment drug 'Axcer' in India.
"AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca's brand 'Axcer', a new brand of ticagrelor," Sun Pharma said in a BSE filing.
The company added that AZPIL already has a brand 'Brilinta' for ticagrelor molecule in India since 2012. Axcer is a drug used for the treatment of acute coronary syndrome (ACS).
Sanjay Murdeshwar, MD, AstraZeneca Pharma India, said: "Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient's risk of another heart attack or cardiovascular-related death."
The company further said: "This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby, benefiting a greater number of ACS patients. It strengthens Sun Pharma's cardiology portfolio with the addition of a new patented therapy."
The Sun Pharma stock was trading at Rs 872 in the morning trade, down 0.79% from its previous close on BSE.
